Price
No data yet.
Social Signal Score
Analyst Ratings
20 analystsRevenue
$9.10M-39.75%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jane Chung
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 129
- Beta
- 1.55
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -9.52
Financials
Revenue
$9.10M-39.8%Net Income
$-31.49MEBITDA
$-20.09MFree Cash Flow
$-22.58MEPS (diluted)
$-1.90Shares Outstanding (diluted)
16.58M+37488.0%Operating Expenses
$31.04MCash & Debt
$142.18MReturn of Capital
$0.00Revenue by Segment (annual)
$71.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $102.48M | $-191.09M | $-22.49 |
| 2024 | $62.04M | $-227.46M | $-29.60 |
| 2023 | $153.73M | $-106.79M | $-17.80 |
| 2022 | $67.77M | $-119.20M | $-23.50 |
| 2021 | $61.88M | $-105.54M | $-22.90 |
| 2020 | $42.72M | $-32.13M | $-9.90 |
| 2019 | $42.74M | $-55.74M | $-24.30 |
| 2018 | $38.42M | $-35.32M | $-15.50 |
| 2017 | $51.74M | $-19.69M | $-28.10 |
| 2016 | $59.73M | $1.70M | $38.60 |
Valuation
STROhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
130+1200.00%Social Signal Score
Mentions (6)
- Newszacks.com·18d ago·Neutral
Here's Why Sutro Biopharma (STRO) is Poised for a Turnaround After Losing 34.2% in 4 Weeks The heavy selling pressure might have exhausted for Sutro Biopharma (STRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
View source ↗ - Newsglobenewswire.com·18d ago·Negative
Sutro Biopharma to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in several upcoming investor conferences.
View source ↗ - Newszacks.com·19d ago·Neutral
Down 39.8% in 4 Weeks, Here's Why Sutro Biopharma (STRO) Looks Ripe for a Turnaround Sutro Biopharma (STRO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
View source ↗ - Newsglobenewswire.com·32d ago·Negative
Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors — STRO-006 is Sutro's second wholly-owned ADC to enter the clinic in less than one year — — Initial clinical data expected in the second half of 2027 — SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format an…
View source ↗ - Newsbenzinga.com·102d ago·Neutral
Why is Sutro Biopharma Stock Falling On Wednesday? Sutro Biopharma, Inc. (NASDAQ:STRO) shares are trading lower on Wednesday as the company faces challenges following its recent update on the STRO-004 Phase 1 study.
View source ↗ - Newsglobenewswire.com·102d ago·Negative
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study – Encouraging early clinical activity i ncluding confirmed and ongoing unconfirmed partial responses with favorable tolerability, and pharmacokinetics (PK) observed in ongoing STRO-004 Phase 1 study – – Strong execution of STRO-004 STRIVE-01 study with rapid enrollment of initial dose escalation cohorts within 7 months; dose optimization ongoing between 4-5 mg/kg – – STRO-006, next
View source ↗
Earnings
Mon, Mar 22(in 4 months)
Consensus estimate $-1.45 per share
Typical surprise -15.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 12$-1.90 vs $-1.64miss
- Wed, Aug 12$-2.33 vs $-2.19miss
- Thu, May 14$-2.94 vs $-2.32miss
- Mon, Mar 23$-5.29 vs $-8.16beat
- Thu, Nov 6$-6.70 vs $-3.94miss
- Thu, Aug 7$-1.40 vs $-3.82beat
Estimates and results for STRO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by STRO officers and directors.
- Bought
- $90k
- Sold
- —
5 trades
0 trades
- Gerber Hans-peterbought
- Chow Gregory K.bought
- Chung Janebought
- Matsui Conniebought
- Pauling Davidbought
95 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in STRO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
